Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trial Designs For Non-Cystic Fibrosis Bronchiectasis May Need Refinement

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA public workshop will consider the design of clinical studies testing antibacterial drugs to treat lung damage caused by recurrent infections.

You may also be interested in...



FDA Guidance On Peripheral Neuropathy Drugs In The Works

The agency is holding a public workshop to discuss therapeutic targets and clinical trial design for disease-modifying agents to treat peripheral neuropathy; many products in recent development have faced challenges.

Defining Exacerbation Could Produce Endpoint For Non-Cystic Fibrosis Bronchiectasis, FDA Told

The agency received input on the natural history of the disease and options for measuring exacerbation to assess therapeutic success during a Sept. 7 workshop.

FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI

A non-inferiority trial with a pre-specified non-inferiority margin is the most likely design for investigational antibacterial drugs targeted at cUTI, according to FDA draft guidance. Primary efficacy endpoint needs to include resolution of symptoms, on top of microbiological success.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel